https://orcid.org/0000-0003-1436-4131
References
- Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S. Precision medicine in ALK rearranged NSCLC: a rapidly evolving scenario. Crit Rev Oncol Hematol. 2018;122:150–156. doi:10.1016/j.critrevonc.2017.12.015
- Krawczyk P, Grenda A, Terlecka P, et al. Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. Sci Rep. 2021;11(1):20939. doi:10.1038/s41598-021-00309-3
- Yasuda Y, Nishikawa Y, Sakamori Y, et al. Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: a case report. Mol Clin Oncol. 2017;7(2):295–297. doi:10.3892/mco.2017.1310
- Charville GW, Padda SK, Sibley RK, Puthillath A, Kwo PY. Resolution of crizotinib-associated fulminant hepatitis following cessation of treatment. Case Rep Hepatol. 2018;2018:3413592.
- Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–241. doi:10.1007/s12072-017-9793-2
- Liu C, Yu H, Long Q, et al. Real world experience of crizotinib in 104 patients with ALK rearrangement non-small-cell lung cancer in a single Chinese Cancer Center. Front Oncol. 2019;9:1116. doi:10.3389/fonc.2019.01116
- Wu YL, Lu S, Lu Y, et al. Results of PROFILE 1029, a Phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(10):1539–1548. doi:10.1016/j.jtho.2018.06.012
- Ota T, Masuda N, Matsui K, et al. Successful desensitization with crizotinib after crizotinib-induced liver injury in ROS1-rearranged lung adenocarcinoma. Intern Med. 2019;58(18):2651–2655. doi:10.2169/internalmedicine.2554-18
- Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–898.
- Guo L, Gong H, Tang TL, Zhang BK, Zhang LY, Yan M. Crizotinib and sunitinib induce hepatotoxicity and mitochondrial apoptosis in L02 cells via ROS and Nrf2 signaling pathway. Front Pharmacol. 2021;12:620934. doi:10.3389/fphar.2021.620934
- Li M, Wang C, Yu Z, et al. MgIG exerts therapeutic effects on crizotinib-induced hepatotoxicity by limiting ROS-mediated autophagy and pyroptosis. J Cell Mol Med. 2022;26(16):4492–4505. doi:10.1111/jcmm.17474
- Nishio M, Kim DW, Wu YL, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. 2018;50(3):691–700. doi:10.4143/crt.2017.280